Processes for the diagnosis, prognosis and monitoring of the progression of chronic lymphoid leukaemia (cll) and/or of systemic lupus erythematosus (sle) using membrane stim 1

Patent metadata

Field	Value
Publication number	US-2018267035-A1
Application number	US-201615554166-A
Country	US
Kind code	A1
Filing date	Feb 26, 2016
Priority date	Feb 26, 2015
Publication date	Sep 20, 2018
Grant date	—

Abstract

Some embodiments are directed to a process for the diagnosis of systemic lupus erythematosus (SLE) and/or of chronic lymphoid leukaemia (CLL) of a subject who may be suffering therefrom, comprising the in vitro detection of the expression of the fraction of the STIM1 protein located at the cell plasma membrane in a biological sample from human and mice. Some other embodiments are directed to a process for predicting the progression and/or monitoring the progression of CLL and/or of SLE, comprising the in vitro detection of the expression of the fraction of the STIM1 protein located at the cell plasma membrane.

First claim

1 . A process for the diagnosis of systemic lupus erythematosus (SLE) and/or of chronic lymphoid leukaemia (CLL) of a subject who may be suffering therefrom, comprising:
in vitro detection of the expression of the fraction of the STIM1 protein located at the cell plasma membrane in a biological sample from the subject.

2 . The process according to claim 1 , wherein the expression is an overexpression of the fraction of the STIM1 protein located at the cell plasma membrane compared with the level of expression of the fraction in a control cell from a subject not suffering from SLE or from CLL, allowing a positive diagnosis of SLE or of CLL.

3 . A process for predicting the progression and/or monitoring the progression of CLL and/or of SLE, comprising:
in vitro detection of the expression of the fraction of the STIM1 protein located at the cell plasma membrane.

4 . The process according to claim 1 , where the cells are chosen from B lymphocytes and T lymphocytes.

5 . The process according to claim 1 , wherein the detection of the fraction of the STIM1 protein located at the plasma membrane also includes detection of the various cell fractions of the STIM1 protein.

6 . The process according to claim 1 , wherein the detection of the expression of the fraction of the STIM1 protein located at the plasma membrane is a measurement of the methylation state of the STIM1 promoter.

7 . The process according to claim 3 , wherein the prediction of the progression is carried out by correlation between the level of expression of the fraction of the STIM1 protein located at the cell plasma membrane and the clinical progression of the disease by calculation of the SLEDAI (Systemic Lupus Erythematosus disease activity index) score for SLE and of the Binet score for CLL.

8 . The process according to claim 1 , wherein the cell is an isolated entire cell.

9 . The process according to claim 3 , wherein the progression is in response to a therapeutic treatment.

10 . The process according to claim 9 , wherein the therapeutic treatment also includes a substance which interacts with the fraction.

11 . The process according to claim 10 , wherein the substance is an antibody directed against a fragment of the STIM1 protein of sequence SEQ ID NO. 3.

12 . The process according to claim 6 , wherein the therapeutic treatment also includes anti-CD20 antibody.

13 . The process according to claim 2 , where the cells are chosen from B lymphocytes and T lymphocytes.

14 . The process according to claim 3 , where the cells are chosen from B lymphocytes and T lymphocytes.

15 . The process according to claim 4 , wherein the prediction of the progression is carried out by correlation between the level of expression of the fraction of the STIM1 protein located at the cell plasma membrane and the clinical progression of the disease by calculation of the SLEDAI (Systemic Lupus Erythematosus disease activity index) score for SLE and of the Binet score for CLL.

16 . The process according to claim 5 , wherein the prediction of the progression is carried out by correlation between the level of expression of the fraction of the STIM1 protein located at the cell plasma membrane and the clinical progression of the disease by calculation of the SLEDAI (Systemic Lupus Erythematosus disease activity index) score for SLE and of the Binet score for CLL.

17 . The process according to claim 6 , wherein the prediction of the progression is carried out by correlation between the level of expression of the fraction of the STIM1 protein located at the cell plasma membrane and the clinical progression of the disease by calculation of the SLEDAI (Systemic Lupus Erythematosus disease activity index) score for SLE and of the Binet score for CLL.

18 . The process according to claim 2 , wherein the cell is an isolated entire cell.

19 . The process according to claim 3 , wherein the cell is an isolated entire cell.

20 . The process according to claim 4 , wherein the cell is an isolated entire cell.

Assignees

• Univ De Bretagne Occidentale Ubo
• Inst Nat Sante Rech Med
• Centre Hospitalier Regional Et Univ De Brest

Inventors

• Renaudineau Yves
• Mignen Olivier
• Debant Marjolaine
• Le Dantec Christelle
• Pers Jacques Olivier

Classifications

• G01N33/575

  for cancer · CPC title

• G01N33/57505

  of the blood, e.g. leukaemia · CPC title

• G01N2800/7028

  Cancer · CPC title

• G01N33/564 Primary

  for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9} · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title